Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Aventis Pharma Limited, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK Trading as: Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
Pentacarinat 300mg Powder for Solution for Injection/Infusion.
| Pharmaceutical Form |
|---|
|
Powder for reconstitution. Sterile, white to almost white powder for use after reconstitution. |
Pentamidine Isetionate 300 mg (Equivalent to 172.4 mg pentamidine base).
| Active Ingredient | Description | |
|---|---|---|
| Pentamidine |
Pentamidine isetionate is an aromatic diamine. It is an antiprotozoal agent which acts by interfering with DNA and folate transformation, and by the inhibition of RNA and protein synthesis. |
| List of Excipients |
|---|
|
Not applicable. |
Cardboard carton containing 5 × 10 ml glass vials each with rubber bung and aluminium ring. Each vial contains 300 mg Pentamidine Isetionate BP.
Aventis Pharma Limited, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
Trading as: Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
PL 04425/0572
Date of first authorisation: 15 June 1988
Date of latest renewal: 17 January 2003
| Drug | Countries | |
|---|---|---|
| PENTACARINAT | Hong Kong, Malta, Netherlands, New Zealand, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
